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Purpose of the study
We are conducting a multicenter, randomized, controlled,
prospective, open trial to evaluate both the efficacy and
toxicity of nevirapine (NVP) (given twice [BID] or once
daily [QD]) in virologically-suppressed patients on a PI-
based HAART. NVP BID dosing is maintained for 2
months after the switch in both groups.
Methods
Patients with >6 months of plasma HIV-RNA (pVL) unde-
tectability (<50 copies/mL) while on therapy with a PI
(boosted or unboosted) plus two NRTIs were considered
for enrolment. Co-infection with HCV and/or HBV was
allowed. All patients were to receive NVP 400 mg/day on
a bid schedule for 2 months and then should be rand-
omized to continue (group A) or to switch to a QD sched-
ule (group B). The NRTI backbone could either be
maintained or changed during the study.
Summary of results
The study enrolled 126 patients (63 in each group). Data-
base was frozen on June 30, 2008, and an interim analysis
was done on 119 patients whose data are available on the
internet-based CRFs. Males are 90%, mean age was 45 ±
8.9 years, 93.1% are Caucasians, 37.8% had AIDS, 24.7%
are HCV+. HIV-RNA pVL result undetectable since mean
of 28 months before switch. At baseline CD4s were 531 ±
262/mm3, total cholesterol 202 ± 49.2 mg/dL, triglycer-
ides 216 ± 140.3 mg/dL, ALT 33 ± 22.6 U/L, and gamma-
GT 53 ± 69.6 U/L (all means ± SD). No statistically signif-
icant differences were present between groups at switch.
After 6 months, mean values in group A vs. B were respec-
tively: CD4s 578 ± 290 and 573 ± 261/mm3; cholesterol
204 ± 42.6 and 195 ± 39.9 mg/dL; triglycerides 135 ± 69.3
and 142 ± 81.7 mg/dL; ALT 51 ± 47.4 and 50 ± 44.3 U/L;
gamma-GT 124 ± 120.9 and 123 ± 176.9 U/L (p values: all
NS). We have so far recorded five virological failures (four
in group A – two at 3rd and two at 4th month, one in B at
4th month). Five patients (three in group A; two in group
B) had grade-4 adverse events (AEs) in the first 2 months
after switch (when both groups were treated with NVP
bid): three episodes of hepatotoxicity (two in HCV+), one
rash (in a black woman), and one for headache and dizzi-
ness. Three additional hepatotoxic grade-4 AEs occurred
afterwards: two in group A (6th month) and one in B (3rd
month), all in patients without HCV/HBV co-infections.
Conclusion
In a switch strategy, NVP given BID or QD seems to be
equally effective and tolerated at this interim analysis. The
influence of a BID induction period on QD dosing would
be fully assessed when all data will be available.
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